TY - JOUR T1 - Glycaemic control and associated factors among patients living with type 2 diabetes in Kinshasa, Democratic Republic of the Congo: a Cross-sectional study JF - medRxiv DO - 10.1101/2023.02.03.23285406 SP - 2023.02.03.23285406 AU - Jean-Pierre Fina Lubaki AU - Olufemi Babatunde Omole AU - Joel Msafiri Francis Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/02/07/2023.02.03.23285406.abstract N2 - Objectives To assess the prevalence and factors associated with glycaemic control to inform potential interventions to improve glycaemic control in Kinshasa, Democratic Republic of the Congo.Design This was a cross-sectional study conducted between November 2011–September 2022. We conducted the selection of the participants through a two-stage sampling process. Participants were asked to complete a structured questionnaire and to provide two millilitres of blood for Hb1AC assay. We performed univariate and multivariable logistic regressions to identify factors associated with poor glycaemic control.Setting A total of 20 randomly selected primary care facilities in Kinshasa, Democratic Republic of the Congo.Participants The sample included 620 patients living with type 2 diabetes with a median age of 60 (IQR=53.5-69) years.Results Most of the study participants were female (66.1%), unemployed (67.8%), having income below the poverty line (76.4%), and without health insurance (92.1%). Two-thirds of the participants (420; 67.6%) had poor glycaemic control. Those participants having taken only insulin (AOR=1.64, 95%CI 1.10 to 2.45) and those on a treatment duration ≥7 years (AOR=1.45, 95%CI 1.01 to 2.08) were associated with increased odds of poor glycaemic control, while being overweight (AOR= 0.47, 95%CI 0.26 to 0.85) and those with uncontrolled blood pressure (AOR=0.65, 95% CI 0.48 to 0.90) were protective for poor glycaemic control.Conclusions This study confirms that poor glycaemic control is common among patients living with type 2 diabetes in Kinshasa, DRC. There is a need for targeted interventions to improve glycaemic control, including metabolic and clinical comorbidity control, lifestyle modifications, and health system factors.What is already known on this topicGlycaemic control is poor in most of the SSA settings, with glycaemic control ranging from 10–60%.Factors associated with glycaemic control are context specific; in the Democratic Republic of the Congo, few studies have investigated poor glycaemic control.What this study addsThe extent of poor glycaemic control among patients living with type 2 diabetes is determined in Kinshasa, Democratic Republic of the Congo.Identification of factors associated with poor glycaemic control in Kinshasa: taking only insulin and having a treatment duration ≥7 years increased the likelihood of poor glycaemic control, while being overweight and having uncontrolled blood pressure were protective.How this study might affect research, practice or policyThe study findings will inform potential interventions to improve glycaemic control in Kinshasa, DRC or similar settings elsewhere.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work. The Protestant University of Congo provided laboratory reagents and facilitated laboratory assays.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees of the Protestant University of Congo (reference number: CEUPC 0067; Date: 05/02/2021) and Human Research Ethics Committee (Medical) of the University of the Witwatersrand (reference number: M210308; Date: 26/08/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets supporting the conclusions in this article are included within the article ER -